Ampio Pharmaceuticals, Inc. Stock price

Equities

AMPE

US03209T3077

Biotechnology & Medical Research

Market Closed - Nyse 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.92 USD +12.20% Intraday chart for Ampio Pharmaceuticals, Inc. -43.21% -55.12%
Sales 2022 - Sales 2023 - Capitalization 1.71M
Net income 2022 -16M Net income 2023 -8M EV / Sales 2022 -
Net cash position 2022 11.88M Net cash position 2023 3.82M EV / Sales 2023 -
P/E ratio 2022
-0.15 x
P/E ratio 2023
-0.19 x
Employees 5
Yield 2022 *
-
Yield 2023
-
Free-Float 97.86%
More Fundamentals * Assessed data
Dynamic Chart
1 day+12.20%
1 week-43.21%
Current month-40.65%
1 month-50.00%
3 months-58.18%
6 months-74.93%
Current year-55.12%
More quotes
1 week
0.70
Extreme 0.7
1.99
1 month
0.70
Extreme 0.7
1.99
Current year
0.70
Extreme 0.7
2.91
1 year
0.70
Extreme 0.7
8.30
3 years
0.70
Extreme 0.7
601.50
5 years
0.70
Extreme 0.7
894.00
10 years
0.70
Extreme 0.7
2 703.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 21-10-12
Director of Finance/CFO 60 19-07-30
Chief Tech/Sci/R&D Officer 70 21-10-12
Members of the board TitleAgeSince
Director/Board Member 75 11-05-31
Chairman 69 21-10-12
Chief Executive Officer 68 21-10-12
More insiders
Date Price Change Volume
24-03-28 0.92 +12.20% 53,291
24-03-27 0.82 +1.05% 101,997
24-03-26 0.8115 -51.70% 327,534
24-03-25 1.68 +0.60% 91,877
24-03-22 1.67 -1.76% 279,866

Delayed Quote Nyse, March 28, 2024 at 04:00 pm EDT

More quotes
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the preclinical development of AR-300, and is conducting studies to evaluate the efficacy of AR-300 in osteoarthritis-related pain. The Company is primarily targeting the clinical development of AR-300 for the treatment of osteoarthritis of the knee (OAK). AR-300 is a small-molecule formulation that has demonstrated anti-inflammatory properties in vitro and protection of cartilage in preclinical rat meniscal tear studies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock
  2. Equities
  3. Stock Ampio Pharmaceuticals, Inc. - Nyse